HER2DX reveals transcriptomic heterogeneity in HER2-positive ductal carcinoma in situ

Ductal carcinoma in situ (DCIS) is a heterogeneous non-invasive breast neoplasm with variable biological and immune-related features. Human epidermal growth factor receptor 2-positive (HER2 +) DCIS is enriched in immune infiltration and aggressive pathological characteristics; however, its molecular heterogeneity remains poorly characterized. HER2DX is a clinically validated genomic assay developed for early-stage HER2+ invasive breast cancer that integrates immune, proliferation, luminal, and HER2-related gene expression signatures. Improved biological characterization of HER2+ DCIS may help identify molecular heterogeneity relevant to future biomarker development and risk-stratification strategies. We retrospectively selected 67 cases of pure HER2 3+ DCIS (pTisN0) diagnosed between 2010 and 2025 based on the availability of adequate archival tissue. All cases underwent centralized pathological review, including confirmation of HER2 status, followed by HER2DX analysis. Clinicopathological variables, stromal tumor-infiltrating lymphocytes (TILs), tumor immune microenvironment (TIME) patterns, and tertiary lymphoid structures (TLS) were centrally evaluated. HER2DX testing was performed on formalin-fixed paraffin-embedded samples. Associations between HER2DX signatures and clinicopathological features were analyzed using correlation and comparative statistical analyses. HER2DX profiles were compared with 496 HER2+ pT1N0 invasive breast cancer cases from established clinical cohorts. HER2DX analysis was successfully performed in all 67 HER2+ DCIS samples and revealed substantial transcriptomic heterogeneity despite homogeneous HER2 3+ expression by immunohistochemistry. The HER2DX immune (IGG) signature strongly correlated with stromal TIL levels, immune-inflamed TIME patterns, and TLS presence, suggesting that HER2DX signatures are associated with biologically relevant features of the immune microenvironment in HER2+ DCIS. The luminal signature was significantly associated with hormone receptor status, while the proliferation signature correlated with Ki-67 expression despite an overall low proliferative profile. Although all DCIS were HER2 3+, 24% and 6% of cases were classified as ERBB2 -medium and ERBB2 -low, respectively. Comparative analyses showed that HER2+ DCIS shares key immune and HER2-related transcriptomic features with stage 1 HER2+ invasive breast cancer, with the main differences observed in proliferation-related biology. HER2DX profiling reveals that HER2+ DCIS comprises biologically distinct tumors with variable immune, luminal, proliferative, and HER2-related transcriptomic features despite homogeneous HER2 protein overexpression. HER2DX signatures showed biologically coherent associations with the immune microenvironment and identified molecular similarities between HER2+ DCIS and stage 1 HER2+ invasive breast cancer. These findings support the use of transcriptomic approaches to improve the biological characterization of HER2+ DCIS.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1186/s13058-026-02409-2
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HER2DX reveals transcriptomic heterogeneity in HER2-positive ductal carcinoma in situ

Felip Garcia, Valeria Sirenko, Fara Brasó‐Maristany, Sandra Cobo et al.
Breast Cancer Research
Breast Cancer Treatment Studies
article

HER2DX reveals transcriptomic heterogeneity in HER2-positive ductal carcinoma in situ

Felip Garcia, Valeria Sirenko, Fara Brasó‐Maristany, Sandra Cobo, Oleguer Castillo, Blanca González‐Farré, Jesús Soberino, Anabel Martínez-Romero, Patricia Galván, Paula Blasco, Sara M. Tolaney, Esther Sanfeliu, Vicente Marco, Paolo Tarantino, Mercedes Marín‐Aguilera, Aleix Prat, Adrienne Gropper Waks, Elia Seguí, Angela Aguirre, Isaac Cebrecos, Laia Paré, Guillermo Villacampa, Vicente Peg, Joel S. Parker
article en

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous non-invasive breast neoplasm with variable biological and immune-related features. Human epidermal growth factor receptor 2-positive (HER2 +) DCIS is enriched in immune infiltration and aggressive pathological characteristics; however, its molecular heterogeneity remains poorly characterized. HER2DX is a clinically validated genomic assay developed for early-stage HER2+ invasive breast cancer that integrates immune, proliferation, luminal, and HER2-related gene expression signatures. Improved biological characterization of HER2+ DCIS may help identify molecular heterogeneity relevant to future biomarker development and risk-stratification strategies. We retrospectively selected 67 cases of pure HER2 3+ DCIS (pTisN0) diagnosed between 2010 and 2025 based on the availability of adequate archival tissue. All cases underwent centralized pathological review, including confirmation of HER2 status, followed by HER2DX analysis. Clinicopathological variables, stromal tumor-infiltrating lymphocytes (TILs), tumor immune microenvironment (TIME) patterns, and tertiary lymphoid structures (TLS) were centrally evaluated. HER2DX testing was performed on formalin-fixed paraffin-embedded samples. Associations between HER2DX signatures and clinicopathological features were analyzed using correlation and comparative statistical analyses. HER2DX profiles were compared with 496 HER2+ pT1N0 invasive breast cancer cases from established clinical cohorts. HER2DX analysis was successfully performed in all 67 HER2+ DCIS samples and revealed substantial transcriptomic heterogeneity despite homogeneous HER2 3+ expression by immunohistochemistry. The HER2DX immune (IGG) signature strongly correlated with stromal TIL levels, immune-inflamed TIME patterns, and TLS presence, suggesting that HER2DX signatures are associated with biologically relevant features of the immune microenvironment in HER2+ DCIS. The luminal signature was significantly associated with hormone receptor status, while the proliferation signature correlated with Ki-67 expression despite an overall low proliferative profile. Although all DCIS were HER2 3+, 24% and 6% of cases were classified as ERBB2 -medium and ERBB2 -low, respectively. Comparative analyses showed that HER2+ DCIS shares key immune and HER2-related transcriptomic features with stage 1 HER2+ invasive breast cancer, with the main differences observed in proliferation-related biology. HER2DX profiling reveals that HER2+ DCIS comprises biologically distinct tumors with variable immune, luminal, proliferative, and HER2-related transcriptomic features despite homogeneous HER2 protein overexpression. HER2DX signatures showed biologically coherent associations with the immune microenvironment and identified molecular similarities between HER2+ DCIS and stage 1 HER2+ invasive breast cancer. These findings support the use of transcriptomic approaches to improve the biological characterization of HER2+ DCIS.

Breast Cancer Research
Harvard University (US), Breast Cancer Research Foundation (US), Hospital Quirónsalud Barcelona (ES), Hospital Clínic de Barcelona (ES), Dana-Farber Cancer Institute (US), Vall d'Hebron Hospital Universitari (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Dana-Farber Brigham Cancer Center (US)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon